Literature DB >> 15209518

Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions.

Bo-Geon Yun1, Wenjun Huang, Natalie Leach, Steven D Hartson, Robert L Matts.   

Abstract

Hsp90 functions to facilitate the folding of newly synthesized and denatured proteins. Hsp90 function is modulated through its interactions with cochaperones and the binding and hydrolysis of ATP. Recently, novobiocin has been shown to bind to a second nucleotide binding site located within the C-terminal domain of Hsp90. In this report, we have examined the effect of novobiocin on Hsp90 function in reticulocyte lysate. Novobiocin specifically inhibited the maturation of the heme-regulated eIF2alpha kinase (HRI) in a concentration-dependent manner. Novobiocin induced the dissociation of Hsp90 and Cdc37 from immature HRI, while the Hsp90 cochaperones p23, FKBP52, and protein phosphatase 5 remained associated with immature HRI. Proteolytic fingerprinting of Hsp90 indicated that novobiocin had a distinct effect on the conformation of Hsp90, and molybdate lowered the concentration of novobiocin required to alter Hsp90's conformation by 10-fold. The recombinant C-terminal domain of Hsp90 adopted a proteolytic resistant conformation in the presence of novobiocin, indicating that alteration of Hsp90/cochaperone interactions was not the cause of the novobiocin-induced protease resistance within Hsp90's C-terminal domain. The concentration dependence of this novobiocin-induced conformation change correlated with the dissociation of Hsp90 and Cdc37 from immature HRI and novobiocin-induced inhibition of Hsp90/Cdc37-dependent activation of HRI's autokinase activity. The data suggest that binding of novobiocin to the C-terminal nucleotide binding site of Hsp90 induces a change in Hsp90's conformation leading to the dissociation of bound kinase. The unique structure and properties of novobocin-bound Hsp90 suggest that it may represent the "client-release" conformation of the Hsp90 machine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15209518     DOI: 10.1021/bi0497998

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  35 in total

1.  Alternative approaches to Hsp90 modulation for the treatment of cancer.

Authors:  Jessica A Hall; Leah K Forsberg; Brian S J Blagg
Journal:  Future Med Chem       Date:  2014-09       Impact factor: 3.808

2.  High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase.

Authors:  Lakshmi Galam; M Kyle Hadden; Zeqiang Ma; Qi-Zhuang Ye; Bo-Geon Yun; Brian S J Blagg; Robert L Matts
Journal:  Bioorg Med Chem       Date:  2007-01-04       Impact factor: 3.641

3.  A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease.

Authors:  Mathias Riebold; Christian Kozany; Lee Freiburger; Michael Sattler; Michael Buchfelder; Felix Hausch; Günter K Stalla; Marcelo Paez-Pereda
Journal:  Nat Med       Date:  2015-02-09       Impact factor: 53.440

Review 4.  Inhibitors and chemical probes for molecular chaperone networks.

Authors:  Jason E Gestwicki; Hao Shao
Journal:  J Biol Chem       Date:  2018-09-13       Impact factor: 5.157

5.  Gambogic acid, a natural product inhibitor of Hsp90.

Authors:  Jason Davenport; Jacob R Manjarrez; Laura Peterson; Brian Krumm; Brian S J Blagg; Robert L Matts
Journal:  J Nat Prod       Date:  2011-04-12       Impact factor: 4.050

6.  Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.

Authors:  Sanil Bhatia; Daniela Diedrich; Benedikt Frieg; Heinz Ahlert; Stefan Stein; Bertan Bopp; Franziska Lang; Tao Zang; Tobias Kröger; Thomas Ernst; Gesine Kögler; Andreas Krieg; Steffen Lüdeke; Hana Kunkel; Ana J Rodrigues Moita; Matthias U Kassack; Viktoria Marquardt; Friederike V Opitz; Marina Oldenburg; Marc Remke; Florian Babor; Manuel Grez; Andreas Hochhaus; Arndt Borkhardt; Georg Groth; Luitgard Nagel-Steger; Joachim Jose; Thomas Kurz; Holger Gohlke; Finn K Hansen; Julia Hauer
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

Review 7.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Authors:  Alison Donnelly; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

8.  Hsp90 charged-linker truncation reverses the functional consequences of weakened hydrophobic contacts in the N domain.

Authors:  Shinji Tsutsumi; Mehdi Mollapour; Christian Graf; Chung-Tien Lee; Bradley T Scroggins; Wanping Xu; Lenka Haslerova; Martin Hessling; Anna A Konstantinova; Jane B Trepel; Barry Panaretou; Johannes Buchner; Matthias P Mayer; Chrisostomos Prodromou; Len Neckers
Journal:  Nat Struct Mol Biol       Date:  2009-10-18       Impact factor: 15.369

9.  The basal flux of Akt in the mitochondria is mediated by heat shock protein 90.

Authors:  Keri A Barksdale; Gautam N Bijur
Journal:  J Neurochem       Date:  2009-01-28       Impact factor: 5.372

10.  The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin.

Authors:  Veronika Kvardova; Roman Hrstka; Dawid Walerych; Petr Muller; Eva Matoulkova; Veronika Hruskova; Dagmar Stelclova; Petr Sova; Borivoj Vojtesek
Journal:  Mol Cancer       Date:  2010-06-15       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.